Wellesley equity firm buys majority of Gardner biotech
Sam Massoni, president and CEO of New England Peptide
Gardner biomanufacturer New England Peptide has received a majority recapitalization from Wellesley private equity firm Ampersand Capital Partners, as the company sets its sights on continued expansion.
New England Peptide designs and manufactures peptide and antibody solutions for drug, vaccine and diagnostic development organizations worldwide. The investment will be used to support the company's worldwide growth initiatives, according to Ampersand, including expanding peptide synthesis capabilities.
The amount of Ampersand's investment was not disclosed.
Ampersand is a middle market private equity firm focused on growth-oriented investments in the healthcare sector with offices in Greater Boston and Amsterdam, Netherlands.
As part of the transaction, José de Chastonay will become the executive chairman of the company's board of directors. He has served in a number of senior management and advisory roles within various research chemical manufacturing organizations, most recently as chief marketing officer and Member of the corporate executive committee at Swiss technology company Bachem Holding AG.
New England Peptide CEO and Founder Sam Massoni said in a statement he was excited to partner with de Chastonay and move forward with assistance from Ampersand.
WBJ Web Partners
Most Recent
Most Recent
0 Comments